All In Biotech

Drug Trial Radar · NCT00102310

YM443 in Subjects With Functional Dyspepsia

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Dose Ranging Study of YM443 in Subjects With Functional Dyspepsia

Last checked: Nov 19, 2026Latest source record: Jan 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

416

Actual

Start

Mar 10, 2004

Primary completion

Mar 11, 2006

Study completion Mar 11, 2006

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
Collaborators
Astellas Pharma US, Inc.
First posted
Jan 27, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.

Conditions

  • Indigestion
  • Nausea

Interventions

  • YM443Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

59 sites in 1 country. Site status is shown where the registry gives one.

  • Dr. Suresh Karne

    Huntsville, Alabama

  • James Thrasher, MD

    Little Rock, Arkansas

  • Dr. Dennis Riff

    Anaheim, California

  • Dr. Peter Winkle

    Cypress, California

  • Dr. Ramin Farsad

    Encinitas, California

  • Dr. Prahalad Jajodia

    Fresno, California

  • Dr. Gurmej Dhillon

    Fresno, California

  • Dr. Steven Duckor

    Orange, California

  • Dr. Theodor Feinstat

    Roseville, California

  • Scott Levenson, MD

    San Carlos, California

  • Dr. Michael Bennett

    San Diego, California

  • Dr. William Snape

    San Francisco, California

  • Dr. Abbass Shafii

    Colorado Springs, Colorado

  • Dr. Julio Salcedo

    Washington D.C., District of Columbia

  • Dr. Daniel Maico

    Gainesville, Florida

  • Dr. Simon Behar

    Hialeah, Florida

  • Wayne Schonfeld, MD

    Hollywood, Florida

  • Dr. Stephen Palte

    Atlanta, Georgia

  • Dr. Nathan Segall

    Atlanta, Georgia

  • Azazuddin Ahmed, MD

    Oak Brook, Illinois

  • Brian Covey, MD

    Dubuque, Iowa

  • Dr. Richard McCallum

    Kansas City, Kansas

  • Robert Braun, MD

    Topeka, Kansas

  • Carroll Steinfeld, MD

    Madisonville, Kentucky

  • David Dulitz, MD

    Metairie, Louisiana

  • Dr. Bal Raj Bhandari

    Monroe, Louisiana

  • Dr. Robert Hardi

    Chevy Chase, Maryland

  • Dr. Braden Kuo

    Boston, Massachusetts

  • Dr. Robert Lustig

    Bridgewater, New Jersey

  • Dr. Rejendra Prasad Gupta

    Trenton, New Jersey

  • Dr. Vitaly Fishbein

    West Orange, New Jersey

  • Dr. Wieslaw Ignatowicz

    Brooklyn, New York

  • Dr. Eugene Bonapace

    Great Neck, New York

  • Dr. James Grendell

    Mineola, New York

  • Dr. William Harlan

    Asheville, North Carolina

  • Dr. John Poulos

    Fayetteville, North Carolina

  • Dr. Peter Eweje

    Jacksonville, North Carolina

  • Dr. Charles Barish

    Raleigh, North Carolina

  • Dr. William Gramley

    Wilmington, North Carolina

  • Dr. Robert Kindel

    Cincinnati, Ohio

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.